Check Before You Invest : Vista Pharmaceuticals Ltd

Snapshot

Q.1 Which industry/sub-sector does Vista Pharmaceuticals Ltd belong to?

Vista Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Vista Pharmaceuticals Ltd a good quality company?

Vista Pharmaceuticals Ltd is a quality company, based on a 10-year financial track record.

Q.3 Is Vista Pharmaceuticals Ltd undervalued or overvalued?

Vista Pharmaceuticals Ltd appears Somewhat Undervalued, as its key valuation ratios are below with their past averages.

Q.4 Is Vista Pharmaceuticals Ltd a good buy now?

Vista Pharmaceuticals Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Vista Pharmaceuticals Ltd?

Vista Pharmaceuticals Ltd revenue growth is -2.1% for FY-2025, which is above its 5-year CAGR of -15.05%, indicating faster growth.

Q.2 Return on capital employed (ROCE) of Vista Pharmaceuticals Ltd?

Vista Pharmaceuticals Ltd Return on capital employed is -8.54% for FY-2025, which is in line with its 5-year historical median of -8.28%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Q.3 Return on Asset of Vista Pharmaceuticals Ltd?

Vista Pharmaceuticals Ltd Return on Asset is -8.41%, which is in line with its 5-year historical median of -8.35%, indicating stable asset utilization efficiency.

Q.4 Return on Equity (ROE) of Vista Pharmaceuticals Ltd?

Vista Pharmaceuticals Ltd Return on equity is -11.47% for FY-2025, which is in line with its 5-year historical median of -11.47%, indicating the business is making similar use of its shareholders capital.

Q.5 Cash conversion cycle of Vista Pharmaceuticals Ltd?

Vista Pharmaceuticals Ltd Cash conversion cycle is 213 days, below its 5-year historical median of 3977 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover	0.18	0.02
ROE	-11.47	-11.47
ROCE	-8.54	-8.28
Cash Conversion Cycle	213 days	3977 days

Q.6 Gross Profit margin of Vista Pharmaceuticals Ltd?

Vista Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is -45.2% for FY-2025, which is above its 5-year median of -243.5%, indicating increasing margins.

Q.7 Operating Profit Margin of Vista Pharmaceuticals Ltd?

Vista Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -38.62% for FY-2025, which is above its 5-year median of -136.58% indicating increasing margins.

Q.8 Net Profit Margin of Vista Pharmaceuticals Ltd?

Vista Pharmaceuticals Ltd Net Profit Margin is -46.14% for FY-2025, is above with its 5-year median of -158.61%, indicating increasing margins.

	Current Level	5-year Historic Median
Gross Profit Margin	-45.2	-243.5
Operating Profit Margin	-38.62	-136.58
Net Profit Margin	-46.14	-158.61

Q.9 Debt to Equity ratio of Vista Pharmaceuticals Ltd?

Vista Pharmaceuticals Ltd Debt-to-Equity ratio is 0.16, which is lower with the industry average of 0.27, indicating lower debt levels in the industry.

Q.10 Debt to cash flow from operations of Vista Pharmaceuticals Ltd?

Vista Pharmaceuticals Ltd Debt to cash flow from operations is -1.06, which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Vista Pharmaceuticals Ltd?

Promoters hold 21.19% of the Vista Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Vista Pharmaceuticals Ltd vs industry peers?

Vista Pharmaceuticals Ltd revenue CAGR is -15.05%, compared to the industry median CAGR of 8.30%, indicating slower growth and losing its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth	-2.1	8.3
Gross Profit Growth	0	14.7
Operating Profit Growth	0	11.4
Net Profit Growth	0	NAN

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover	0.18	0.81
ROE	-11.47	9.49
ROCE	-8.54	11.91
Cash Conversion Cycle (days)	213.1	85

Valuation & price assessment

Q.1 Stock return of Vista Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -6.1% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price CAGR	-6.1%	-8.2%	-3.5%	-21.9%

Q.3 Valuation ratios of Vista Pharmaceuticals Ltd vs historical?

The current P/E is lower that its historical median.

Q.4 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	-	98.12	31.09
Price to Book	1.16	1.26	2.85
Price to Sales	5.67	12.10	2.79
EV to EBITDA	-7.21	-26.90	15.87

Check more companies

5. Wockhardt

9. Pfizer

10. Neuland Laboratories

Check trending companies

1. JSW Infrastructure Ltd.

2. Aditya Birla Fashion and Retail Ltd.

3. Zydus Lifesciences Ltd.

4. Techno Electric & Engineering Company Ltd.

5. Cello World Ltd.